Ozempic Isn’t “Too New” — Here’s the 20-Year Truth

Transcript

Are GLP 1 medications like Ozempic and Mounjaro really “too new” to trust? 

In this episode, I break down one of the most common fears patients bring into the clinic when discussing GLP 1 medications for weight loss and diabetes treatment. 

We discuss:
 • How long GLP 1 medications have actually been studied
 • Why Ozempic, Mounjaro, Wegovy, and related medications are not experimental treatments
 • The difference between internet fear and evidence based medicine
 • What physicians look at when evaluating medication safety
 • Which patients should not take GLP 1 medications
 • Why patients often feel overwhelmed by conflicting health information online 

I also explain the importance of physician patient allyship when navigating obesity treatment and why understanding the science behind these medications matters more than social media fear mongering. 

If you have ever wondered whether Ozempic or Mounjaro are truly safe long term, this episode will help you understand what decades of clinical data actually show.

Questions for Dr. Takem and the team

💡 Start your journey today with Maryland Primary Care & Wellness
Book your consultation: https://www.maryland-primarycare.com/